Budget Impact Analysis of Biosimilar Natalizumab in the US
The American Journal of Managed Care · 2024
DOI: 10.37765/ajmc.2024.89558 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Managed Care, 2024. Verfasst von Edward Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sandoz Inc, 100 College Rd W, Princeton, NJ 08540. Email: anna-1.chen@sandoz.com. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals, Budgets. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sandoz Inc, 100 College Rd W, Princeton, NJ 08540. Email: anna-1.chen@sandoz.com.
Zitieren
APA
Li, E., Goh, A., Gupta, S., Schauf, M., Chen, A., & Hartung, D. M. (2024). Budget Impact Analysis of Biosimilar Natalizumab in the US. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2024.89558
Vancouver
Li E, Goh A, Gupta S, Schauf M, Chen A, Hartung DM. Budget Impact Analysis of Biosimilar Natalizumab in the US. The American Journal of Managed Care. 2024. doi:10.37765/ajmc.2024.89558
BibTeX
@article{Li2024,
author = {Li, Edward and Goh, Adrian and Gupta, Soni and Schauf, Marion and Chen, Anna and Hartung, Daniel M},
title = {Budget Impact Analysis of Biosimilar Natalizumab in the US},
journal = {The American Journal of Managed Care},
year = {2024},
doi = {10.37765/ajmc.2024.89558}
}
EUVIMED